Mean exposure to teduglutide
Patients who completed the extension study until the interim data cut-off point received teduglutide up to a maximum of 14 months (SHP633-306) or 57 months (TED-C14-004). The mean extents of teduglutide exposure only in TED-C14-004 and SHP633-306 were 26.8 ± 17.0 months and 4.8 ± 1.6 months, respectively. The mean cumulative extents of exposure to teduglutide for patients who completed both the core and the extension study treatments were 54.3 ± 1.7 and 12.7 ± 1.0 months for patients from TED-C14-004 and SHP633-306, respectively.